We have previously reported that clopidogrel treatment, compared with ticagrelor treatment, was associated with a higher incidence of severe pulmonary infections or sepsis and an increased mortality.20 This finding was accompanied with a lower leucocyte count at one month and lower mean CRP‐hs and IL‐6 concentrations in patients randomized to clopidogrel, indicating possible effects of the randomized antiplatelet treatment on immune signaling.20 However, we found no evidence that the randomized antiplatelet treatment affected IL‐18 concentrations. This evidence concerns the gene CRP and Sepsis.